newsfilter
← Latest News
GlobeNewswire·

Landmark Nature Health Study Demonstrates the Effectiveness of DeepHealth's Novel AI-Powered Breast Cancer Detection Workflow

RDNT
  • RadNet, Inc. & its subsidiary DeepHealth announced results from the largest real-world analysis of AI-driven breast cancer screening in U.S. history, published in Nature Health.
  • The AI-Supported Safeguard Review Evaluation (ASSURE) study examined mammograms from over 579,000 women across 109 community-based imaging sites in California, Delaware, Maryland & New York.
  • The study compared state-of-the-art 3D mammography to a novel AI-driven protocol combining DeepHealth's FDA-cleared CADe/x software with a Safeguard Review workflow that triggers expert review for high-suspicion cases.
  • The AI-powered workflow increased the cancer detection rate by 21.6% compared to standard 3D mammography while maintaining recall rates within American College of Radiology guidelines.
  • Positive predictive value increased by 15% & the workflow delivered equitable results across diverse racial, ethnic & breast density patient groups.
  • Black women, who face 40% higher breast cancer mortality in the U.S., showed significant benefits with over 150,000 enrolled in the study.
  • Women with dense breasts experienced a 22.7% boost in cancer detection rates using the AI workflow due to their increased risk & diagnostic challenges.
  • The study took place at community imaging centers where the AI-enabled workflow was provided to all patients at no additional charge to avoid selection bias.
  • RadNet's Enhanced Breast Cancer Detection™ (EBCD™) program, launched nationwide in 2023, utilizes DeepHealth's Breast Suite applications to detect suspicious lesions.
  • RadNet operates a network of 407 outpatient imaging centers across eight states & employs approximately 11,000 team members.
  • DeepHealth serves as RadNet's Digital Health segment umbrella brand, leveraging AI for operational efficiency & improved clinical outcomes in multiple health areas.